2. Search Result
Search Result
Results for "

glycogen synthase kinase 3β

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Peptides

1

Natural
Products

3

Recombinant Proteins

8

Antibodies

1

Click Chemistry

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16294
    LY2090314
    Maximum Cited Publications
    20 Publications Verification

    		 GSK-3 Cancer
    LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
    LY2090314
  • HY-113914
    9-ING-41
    5+ Cited Publications

    Elraglusib

    		 GSK-3 Apoptosis Autophagy Cancer
    9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents [3] .
    9-ING-41
  • HY-59090
    1-Azakenpaullone
    3 Publications Verification

    1-Akp

    		 GSK-3 Neurological Disease Metabolic Disease
    1-Azakenpaullone (1-Akp) is a highly selective and ATP-competitive inhibitor of glycogen synthase kinase-3 β (GSK-3β), with an IC50 value of 18 nM .
    1-Azakenpaullone
  • HY-11001
    PHA-793887
    4 Publications Verification

    		 CDK Apoptosis Cancer
    PHA-793887 is a potent, ATP-competitive CDK inhibitor, can inhibit Cdk2, Cdk1, Cdk4, and Cdk9 with IC50s of 8 nM, 60 nM, 62 nM and 138 nM, respectively, and also inhibits glycogen synthase kinase 3β with an IC50 of 79 nM.
    PHA-793887
  • HY-107531
    A 1070722

    		GSK-3 Neurological Disease Cancer
    A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a Ki of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .
    A 1070722
  • HY-139254
    Indirubin-3′-oxime

    IDR3O; I3O

    		 CDK GSK-3 JNK Wnt Neurological Disease
    Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes [3].
    Indirubin-3′-oxime
  • HY-141480
    GSK-3β inhibitor 3
    1 Publications Verification

    		 GSK-3 Apoptosis Cancer
    GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia .
    GSK-3β inhibitor 3
  • HY-P10605
    GSK3β-peptide

    		Akt GSK-3 Cancer
    GSK3β-peptide is a substrate mimetic peptide of glycogen synthase kinase 3-β (GSK3-β) that can bind to the active site of GSK3-β and mimic the behavior of a real substrate. GSK3β-peptide can be used to develop substrate mimetic inhibitors of Akt as potential anticancer drugs .
    GSK3β-peptide
  • HY-121035
    7BIO

    7-Bromoindirubin-3-Oxime

    		 CDK GSK-3 Neurological Disease
    7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice [1].
    7BIO
  • HY-126144A
    (E/Z)-GSK-3β inhibitor 1

    		GSK-3 Metabolic Disease
    (E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM .
    (E/Z)-GSK-3β inhibitor 1
  • HY-148132
    GSK-3β inhibitor 11

    		GSK-3 Neurological Disease
    GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC50=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .
    GSK-3β inhibitor 11
  • HY-169632
    GSK3β-IN-1

    		GSK-3 Neurological Disease
    GSK3β-IN-1 (compound 1) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC50=65 nM), which can be used in the study of Alzheimer's disease .
    GSK3β-IN-1
  • HY-175850
    GSK-3β-IN-28

    		GSK-3 Apoptosis NF-κB c-Myc Cancer
    GSK-3β inhibitor 28 is selective and non-competitivea glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 14.82 nM. GSK-3β inhibitor 28 can upregulate the expression level of phosphorylated GSK-3β and downregulate the expression of p-NF-κB, P65, C-myc and Cyclin D1. GSK-3β inhibitor 28 can induce cells apoptosis, G1 phase arrest and inhibit migration. GSK-3β inhibitor 28 can be used for the research of cancer, such as colorectal cancer .
    GSK-3β-IN-28
  • HY-170491
    GSK-3β inhibitor 23

    		GSK-3 Infection Neurological Disease
    GSK-3β inhibitor 23 (Compound 11726169) is the inhibitor for glycogen synthase kinase-3, that inhibits GSK-3β and GSK-3α with IC50 of 12.1 nM and 18.8 nM. GSK-3β inhibitor 23 exhibits antiviral activity against HIV 1. GSK-3β inhibitor 23 exhibits good metabolic stablility in mouse/human liver microsomes and plasma, but poor Caco-2 permeability (which predicts low oral bioavailability) .
    GSK-3β inhibitor 23
  • HY-W780130
    SkQR1 hydroxide

    		Mitochondrial Metabolism GSK-3 Inflammation/Immunology
    SkQR1 hydroxide is a mitochondrial targeted antioxidant. SkQR1 hydroxide can inhibit glycogen synthase kinase 3β (GSK3β) in the brain. SkQR1 hydroxide has a significant memory promoting effect. SkQR1 hydroxide can be used for research related to brain memory .
    SkQR1 hydroxide
  • HY-133102
    Dihydronarwedine

    Lycoraminone

    		 GSK-3 Neurological Disease
    Dihydronarwedine (Lycoraminone) is the alkaloid. Dihydronarwedine inhibits 39% activity of glycogen synthase kinase-3β (GSK-3β) at a concentration of 10 μM .
    Dihydronarwedine
  • HY-114270
    JGK-263

    		GSK-3 Neurological Disease
    JGK-263 is an orally active Glycogen synthase kinase-3β (GSK-3β) inhibitor. JGK-263 exhibits neuroprotective effect and can improve motor function. JGK-263 can be used for the research of neurological disease, such as amyotrophic lateral sclerosis (ALS) .
    JGK-263
  • HY-107529
    TC-G 24

    		GSK-3 Neurological Disease Metabolic Disease
    TC-G 24 (Compound 24) is a potent, selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 17.1 nM. TC-G 24 can cross the BBB and can be used for studying many diseases such as type 2 diabetes mellitus, stroke, Alzheimer, and other related diseases .
    TC-G 24
  • HY-136679
    TD114-2

    		GSK-3 Neurological Disease Metabolic Disease
    TD114-2 (cmpound 29) is a potent and highly selective inhibitor of glycogen synthase kinase-3β (GSK-3β) (IC50=48 nM). TD114-2 is associated with the hydrogen bond formation of arginine 141 (ARG141) specific to GSK-3β, an amino acid that is often a negatively charged residue in other kinases, which determines the high selectivity of GSK-3β. TD114-2 can be used in the study of diabetes, neurodegenerative diseases and other diseases associated with GSK-3β .
    TD114-2
  • HY-161667
    GSK-3β/HDAC-IN-1

    		GSK-3 HDAC Neurological Disease
    GSK-3β/HDAC-IN-1 (Compd 4) is a brain-penetrant and first in class dual non-ATP-competitive Glycogen Synthase Kinase 3β/Histone Deacetylases (GSK-3β/HDACs) Inhibitor with IC50s of 0.142, 0.03 and 0.045 μM against GSK-3β, HDAC2 and HDAC6, respectively. GSK-3β/HDAC-IN-1 can be used for Alzheimer’s disease research .
    GSK-3β/HDAC-IN-1
  • HY-P3713
    Presenilin 1 (349-361)

    		GSK-3 Cancer
    Presenilin 1 (349-361) is an active petide, and synthetic peptides representing amino acids 349–361 can be phosphorylated by glycogen synthase kinase-3β(GSK3β) in vitro. Presenilin 1 (349-361) can be used for the research of various diseases .
    Presenilin 1 (349-361)
  • HY-174398
    GSK-3β/HDAC-IN-2

    		GSK-3 HDAC Tau Protein Neurological Disease
    GSK-3β/HDAC-IN-2 is a potent inhibitor of GSK-3β (IC50 = 0.04 μM), HDAC2 (IC50 = 1.05 μM, Ki = 0.070 μM) and HDAC6 (IC50 = 1.52 μM, Ki = 0.017 μM). GSK-3β/HDAC-IN-2 inhibits HDAC2 and HDAC6 activities and blocks tau hyperphosphorylation. GSK-3β/HDAC-IN-2 exerts neuroprotective effects and shows no significant toxicity. GSK-3β/HDAC-IN-2 can be used in the research of Alzheimer's disease.
    GSK-3β/HDAC-IN-2
  • HY-182978
    Pomalidomide-C3-O-C4-O-C3-NH2

    		E3 Ligase Ligand-Linker Conjugates Others
    Pomalidomide-C3-O-C4-O-C3-NH2 is an E3 ligase ligand-linker conjugate that contains Pomalidomide (HY-10984). Pomalidomide-C3-O-C4-O-C3-NH2 can be used for the synthesis of PROTACs targeting glycogen synthase kinase 3β (GSK-3β), such as PROTAC GSK-3β Degrader-1 (HY-149845) .
    Pomalidomide-C3-O-C4-O-C3-NH2
  • HY-148133
    GSK-3β inhibitor 12

    		GSK-3 Neurological Disease
    GSK-3β inhibitor 12 (Compound 15) is a GSK-3β inhibitor. GSK-3β inhibitor 12 is applicable to the research of Alzheimer's disease .
    GSK-3β inhibitor 12
  • HY-16294G
    LY2090314

    		GSK-3 Cancer
    LY2090314 (GMP) is LY2090314 (HY-16294) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
    LY2090314
  • HY-107531R
    A 1070722 (Standard)

    		Reference Standards GSK-3 Neurological Disease Cancer
    A 1070722 (Standard) is the analytical standard of A 1070722 (HY-107531). This product is intended for research and analytical applications. A 1070722 is a potent and selective glycogen synthase Kinase 3 (GSK-3) inhibitor, with a Ki of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .
    A 1070722 (Standard)
  • HY-181248
    BChE-IN-49

    		Cholinesterase (ChE) Bcl-2 Family GSK-3 Wnt β-catenin Amyloid-β Apoptosis Interleukin Related TNF Receptor Neurological Disease
    BChE-IN-49 is an orally active BChE inhibitor with IC50 values of 0.73 μM and 6.43 μM against BChE and AChE, respectively. BChE-IN-49 reduces AChE levels to inhibit the degradation of acetylcholine. By inhibiting GSK-3β, BChE-IN-49 potently activates the Wnt/β-catenin signaling pathway, exerting potent anti-Aβ, antioxidant, anti-neuroinflammatory and anti-apoptotic effects. BChE-IN-49 can be used in research related to Alzheimer's disease .
    BChE-IN-49

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: